Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blossom: YM178 (Mirabegron) in Overactive Bladder
NCT01604928Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2004
- Primary completion
- Jan 2005
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of mirabegron in overactive bladder (OAB) (4 arms), sponsored by Astellas Pharma. Primary endpoint: Change from baseline in mean number of micturitions per 24 hours at 4 weeks. Started Apr 2004; status: completed.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT01604928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01604928.